ProMIS Neurosciences, Inc. (PMN)
NASDAQ: PMN · Real-Time Price · USD
10.61
-0.36 (-3.24%)
Apr 7, 2026, 11:06 AM EDT - Market open
ProMIS Neurosciences Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
11
Market Cap
95.10M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Verrica Pharmaceuticals | 35.58M |
| Seer, Inc. | 16.58M |
| Pyxis Oncology | 13.86M |
| Coya Therapeutics | 7.95M |
| Inovio Pharmaceuticals | 65.34K |
PMN News
- 13 days ago - ProMIS Neurosciences Announces Full Year 2025 Financial Results and Provides Corporate Highlights - GlobeNewsWire
- 20 days ago - ProMIS Neurosciences to Present Data on ALS & Parkinsons Disease Programs at Alzheimer's Disease/Parkinson's Disease 2026 International Conference (AD/PD™) - GlobeNewsWire
- 2 months ago - ProMIS Neurosciences to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 - GlobeNewsWire
- 2 months ago - ProMIS Neurosciences Announces Up to $175 Million Private Placement Financing - GlobeNewsWire
- 3 months ago - ProMIS Neurosciences Exceeds Target Enrollment in PRECISE-AD Phase 1b Clinical Trial of PMN310 in Alzheimer's Disease - GlobeNewsWire
- 4 months ago - ProMIS Neurosciences Announces New Peer-Reviewed Publication Highlighting Selective Targeting of Toxic Oligomers for Potential Clinical Benefit and Reduced ARIA Risk - GlobeNewsWire
- 4 months ago - ProMIS Neurosciences Announces New Peer-Reviewed Publication Showing Plasma pTau as a Predictive Early Endpoint in Alzheimer's trials, Supporting its Ongoing Phase 1b PRECISE-AD trial with PMN310 - GlobeNewsWire
- 4 months ago - ProMIS Neurosciences to Participate in the 8th Annual Evercore Healthcare Conference - GlobeNewsWire